Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.785 USD | +5.29% | -2.03% | -17.49% |
05-02 | Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos | MT |
05-01 | Malin Corp investee signs agreement with Astellas Pharma | AN |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.49% | 256M | |
+5.03% | 109B | |
+10.83% | 105B | |
-0.38% | 22.25B | |
-12.31% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-9.07% | 16.85B | |
+4.60% | 13.76B | |
+34.81% | 12.46B |
- Stock Market
- Equities
- PSTX Stock
- News Poseida Therapeutics, Inc.
- Poseida Therapeutics : Piper Sandler Adjusts Poseida Therapeutics PT to $19 From $17, Maintains Overweight Rating